bardoxolone (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

AdultPediatric

Chronic Kidney Disease

Pending FDA approval for patients aged ≥12 years with chronic kidney disease caused by Alport syndrome

Chronic Kidney Disease

Pending FDA approval for patients aged ≥12 years with chronic kidney disease caused by Alport syndrome

Next:

Pharmacology

Mechanism of Action

Activates nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting proinflammatory signaling

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.